Akeso, Inc.

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:25 30/05/2024 pm IST			5-day change	1st Jan Change
32 ^HKD	+0.63%		-33.40%	-31.03%

24/05	Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut	MT
24/05	Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%	MT

Akeso, Inc. Announces Appointment of Zhang Xinfeng as Senior Vice President

July 17, 2020 at 03:42 am IST

The board of directors of Akeso, Inc. announced the appointment of Dr. Zhang Xinfeng as senior vice president of the Company.

Latest news about Akeso, Inc.

Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut	24/05	MT
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%	24/05	MT
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection	24/05	CI
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	24/04	MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	24/04	CI
Akeso to Raise Over HK$1 Billion Via Share Sale	22/03	MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	19/03	MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03	CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	06/03	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	05/03	MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	05/03	CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	23/02	MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02	RE
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3%	09/02	MT
Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI	23/01	CI
Akeso, Inc. Announces Innovative Clinical Development Roadmap	08/01	CI
Chinese Medical Regulator Accepts Akeso’s Supplemental New Drug Application for Gastric Cancer Therapy	05/01	MT
Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer	05/01	CI
Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023	15/12	CI
Akeso Publishes Results from Three Investigator-Initiated Trials	05/12	CI
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate its Innovation Globalization Strategy	28/11	CI
Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival for First-Line Treatment of Recurrent/Metastatic Cervical Cancer	27/11	CI
Akeso's Phase 3 Trial for Cervical Cancer Attains Progression-Free Survival	23/11	MT
Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer	23/11	CI
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)	07/11	CI

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

20/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Akeso, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.5 CNY

Average target price

54.58 CNY

Spread / Average Target

+84.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AKESO, INC.	-31.03%	3.52B
VERTEX PHARMACEUTICALS INCORPORATED	+8.49%	114B
REGENERON PHARMACEUTICALS, INC.	+10.25%	104B
ARGENX SE	-1.83%	22.57B
BIONTECH SE	-3.51%	22.5B
GENMAB A/S	-10.39%	17.95B
WUXI APPTEC CO., LTD.	-41.90%	16.48B
BEIGENE, LTD.	-14.35%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+3.84%	13.55B
SAREPTA THERAPEUTICS, INC.	+27.97%	10.99B

Bio Therapeutic Drugs

Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Akeso, Inc. Announces Appointment of Zhang Xinfeng as Senior Vice President

Latest news about Akeso, Inc.

Chart Akeso, Inc.

Company Profile

Income Statement Evolution

Ratings for Akeso, Inc.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs